secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0001689548-24-000041
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis reports 100% response rate in PRAX-628 Phase 2a epilepsy PPR study; plans focal onset trial H2 2024
--------------------------------------------------------------------------------

- 15 mg cohort: 100% total response (20% partial, 80% complete); 45 mg cohort: 100% complete response.
- Combined cohort: 88% complete response, 12% partial response; 8 of 9 evaluable patients responded.
- Safety consistent with Phase 1; pharmacokinetic analysis confirmed therapeutic exposures.
- Company plans to initiate a focal onset epilepsy efficacy study in second half of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954824000041/0001689548-24-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954824000041/prax-20240326.htm
  HTML page:      https://secwatch.observer/filing/0001689548-24-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer